From: King Kimchi[consulting012345@gmail.com]

Sent: Thur 10/1/2020 5:40:14 PM (UTC)

To: compliance[compliance@Safechain.com]; Abbie Divilio[AbbieD@Safechain.com]

Attachment: CDGXKA.pdf

GOVERNMENT EXHIBIT 180 1:24-cr-20255-WPD

GX 180.001 CTRL00378519

Drug Supply Chain Security Act Document

(TI) Transaction Information

Drug Name, Strength, Dosage Form, Container Size:

BIKTARVY 30CT

NDC: 61958-2501-01 Lot Number Quantity Unique Serial # 5 **CDGXKA**

INV 6901 Reference Number: INVOICE **Document Type:**

09/28/2020 **Reference Date:**

(TH) Transaction History

Manufacturer's Name: Gilead Sciences, Inc.

Manufacturer's information333 Lakeside Drive, Foster City, CA 94404

SOLD TO: SHIPPED TO:

Name: Rochester Drug Co-Op Inc 116 Lehigh Dr #3013 Address: Fairfield, NJ 07004

Rochester Drug Co-Op Inc Name: 116 Lehigh Dr #3013 Address: Fairfield, NJ 07004

Date Received & Ref: 08/18/20 Date Purchased & Ref: 08/18/20 PO#R2389

SOLD TO:

Name: Instacare Pharmacy 235-20 147th Ave Address:

Rosedale, NY 11422

SHIPPED TO:

Instacare Pharmacy Name: 235-20 147th Ave Address:

Rosedale, NY 11422

Date Purchased & Ref: PO#001IC518 09/02/20 Date Received & Ref: 09/02/20

SOLD TO:

Name: **BOULEVARD 9229 LLC** 9229 QUEENS BLVD STE Address:

11 REGO PARK, NY 11374

SHIPPED TO:

Name: **BOULEVARD 9229 LLC** Address: 9229 QUEENS BLVD STE

11 REGO PARK, NY 11374

Date Purchased & Ref: 09/15/20 Date Received & Ref: 09/15/20 PO#01209744

SOLD TO:

Name: SAFE CHAIN SOLUTIONS, LLC **822 CHESAPEAKE DR**

Address: **CAMBRIDGE MD 21613**

09/28/20

SHIPPED TO:

Name: SAFE CHAIN SOLUTIONS, LLC

822 CHESAPEAKE DR Address: **CAMBRIDGE MD 21613**

09/28/20 Date Purchased & Ref: Date Received & Ref: PO#9311

SOLD TO: Name:

Address:

SHIPPED TO:

Name: Address:

Date Purchased & Ref: Date Received & Ref:

(TS) Transaction Statement: This Company complied with each applicable subsection of FDCA Sec. 581 (27) (A) - (G)

(A) is authorized as required under the Drug Supply Chain Security Act;

(B) received the product from a person that is authorized as required under the Drug Supply Chain Security Act;

(C) received transaction information and a transaction statement from the prior owner of the product, as required under section 582;

(D) did not knowingly ship a suspect or illegitimate product;

(E) had systems and processes in place to comply with verification requirements under section 582;

(F) did not knowingly provide false transaction information; and

(G) did not knowingly alter the transaction history.

Page: 1 of 1 pages.

GX 180.002 CTRL00378520